Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAvigen Granted AV411 Patent for Neuropathic Pain
Avigen, 05/21/09
Avigen, Inc. a biopharmaceutical company, announced that it has been granted United States Patent No. 7,534,806, entitled "Method for Treating Neuropathic Pain and Associated Syndromes." The patent covers the treatment of neuropathic pain with therapeutic doses of AV411, including syndromes like diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia, and neuropathic pain associated with stroke or accompanying cancer chemotherapy. Avigen anticipates additional patents will be issued covering indications that include addiction, delirium, and psychotic disorders, as well as composition of matter claims on AV411 analogs. AV411 is marketed in Japan but not approved for any indication in the United States.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient onsiderations and the role of lisdexamfetamine
Therapeutics and Clinical Risk Management, 12/09/09
Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD)
Archives of Gerontology and Geriatrics, 12/09/09
Neuroimaging to assess safety and efficacy of AD therapies
Expert Opinion on Investigational Drugs, 12/09/09
Sponsor
Article Search
Sponsor